making microbiology easy

Exploration of microbiota

Supporting microbiota-linked projects

Smaltis supports the various stages of development of your products derived from or acting on the microbiota, in order to provide data on your candidates and compile the regulatory files necessary for their marketing.

Context

A microbiota is the set of microorganisms (bacteria, archaea, yeasts, fungi, viruses) living in a specific environment. This ecological community consists of commensal microorganisms present in and on all multicellular organisms studied to date. In humans and animals, there are different microbiota (skin, vaginal, urinary, respiratory, ENT, intestinal…), whose composition differs from one another.

In its normal state, a microbiota is made up of microorganisms living in symbiosis with each other and with their host, characterized by a homeostasis dialogue influencing different physiological systems. In case of dysbiosis, this dialogue is disrupted, and can cause many pathologies.

This is why the human and animal microbiota is one of the focus of medical research in the 21st century. Indeed, acting on this dysbiosis is very promising and represents today a new medical discipline, both in terms of diagnosis, prevention and treatment of diseases, as well as the generation of new pharmacological products from a microbiota. This research allows the discovery of new key biomarkers for the diagnosis of pathologies, and leads to a more personalized medicine. In addition, the discoveries are leading to the identification of different preventive or therapeutic strategies, via the modulation of microorganisms, the substances they produce and the microbiome as a whole. This involves modifying lifestyle habits, using prebiotics, probiotics, post-biotics or synbiotics, fecal transplants, Live Biotherapeutic Products, or any other compound that preserves or rebalances the microflora… with the aim of preserving each person’s health capital.

The field of possibilities is very huge and many experiments are necessary to characterize these products and evaluate their effectiveness. This is where Smaltis comes in, by accompanying you in these evaluations.

Studied Products and Microbiota

Smaltis supports the development of various compounds or microorganisms. Depending on their target, different microbiota and bacteria can be studied, in a pathological context or not.
The fields studied are animal, human and environmental health.

Intestinal, Vaginal, Oral, Pulmonary, Urinary Microbiota…
Soil, Aquatic Microbiota

Microbiotic Medicinal Products – Live Biotherapeutic Products – Non-Living Biotherapeutic Products –

Prebiotics, Probiotics, Postbiotics, Synbiotics – Phages – Other compounds

Our offer

Intervention on the different key stages of the marketing process

Strain screening & characterization

Genotype, phenotype, biochemical identification, whole genome sequencing, biological activity, metabolite production, antibiotic susceptibility, virulence, gene transfer, genetic stability, gastro-resistance, adhesion, presence of plasmids and mobile genetic elements, viability, antagonistic effect towards pathogenic bacteria…

Bacterial strain optimization

Deletion of phagic sequences or other genomic contaminants, deletion of genes related to diffusion, reduction of transmission of antibiotic resistance and pathogenicity, attenuation of virulence factors, elimination of plasmids, insertion of genes for the production of recombinant proteins, optimization of gene expression…

Mechanism of action

Tools and Models designed to assess efficacy.
Functional screening – Threshold dose – Description of interactions with bacteria – Determination of biomarkers – Bioassays – Companion diagnostic

Microbiota description

Next Generation Sequencing to describe the microbiota through metagenomic and metatranscriptomic analysis
Post-metagenomic studies to explain the evolution of a microbiota induced by a candidate

Analytical controls

Stability, purity, identity, efficiency level, expression rate of recombinant proteins…

Process development

Specific procedure to monitor strains or compounds from strains
Determination of the best culture conditions
Partnership with other companies for the production of recombinant proteins

Tools and Models

Thanks to its microbiology, molecular biology and cell biology platforms, Smaltis is able to work with different models and samples, and to propose operating procedures specifically adapted to the projects. 

Models:

› Cultures & co-cultures of aerobic or anerobic bacteria, and yeasts of interest
          → Available strain collections 
          → Customized bacterial strains construction

› Cellular infection
         → Cellular infection models and cellular response on intestinal cells (Caco2, T84, HT29), pulmonary cells (A549, NCI-H820), macrophages (murine macrophages J774A.1, THP-1 monocytes)…

› Biological samples
          → Biopsies, skin explants, stools…

Example of achievement

Study in the context of Crohn disease: support of the development of a compound acting on FimH protein of E. coli bacterial strains involved in acute over-inflammation in patients suffering from this pathology.

Preclinical phase:
Evaluation of the adhesion and invasion properties of AIEC (adherent invasive E. coli) strains, on an intestinal epithelial cell line
Development of an aggregation assay to visualize the interaction between the compound and the FimH proteins of the strains of interest

Phase I b clinical trial:
Development of a method to isolate “biomarker” bacteria from intestinal biopsies

Continued work on the Phase II clinical trial

Compound developed by Enterome then Takeda